Safety of 3-month flushing interval for prevention of occlusion in totally implantable venous access ports: An analysis focused on intraluminal clots
The Journal of Vascular Access · 2025
DOI: 10.1177/11297298241282822 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Vascular Access, 2025. Verfasst von Woo Jin Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Catheterization, Central Venous, Catheters, Indwelling, Central Venous Catheters, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
This study aimed to assess the safety and feasibility of a 3-month flushing interval for totally implantable venous access ports (TIVAPs), particularly regarding intraluminal clot formation.
Methods
Between May 2017 and September 2018, we established a single-center cohort of 151 patients who were referred for TIVAP removal and categorized them into three flushing-interval groups: A (⩽1 month), B (1–2 months), and C (2–3 months). Odds ratios (OR) with 95% confidence intervals (CI) were computed using logistic regression to determine the risk of intraluminal clot occurrence. To compare clot lengths among the groups, we employed linear regression. Restricted cubic splines were used to model the flushing interval as a continuous variable.
Results
Compared to Group A, Groups B and C had adjusted ORs of 0.82 (0.35–1.92) and 0.78 (0.29–2.11) for intraluminal clot risk. Occlusion was rare (1/151; 0.7%) and successfully treated with mechanical recanalization. Adjusted differences in clot length compared to Group A were 0.01 (−0.85 to 0.87) for Group B and −0.23 (−1.21 to 0.76) for Group C. Spline regression analysis showed no significant association between the flushing interval and clot length ( p for trend = 0.84).
Conclusion
The incidence and burden of intraluminal clots did not increase significantly within the first 3 months. Occlusion was rare, even in the presence of clots, and was successfully treated. Therefore, a 3-month flushing interval appears to be a safe and practical option, aligning with the common recommendation for surveillance intervals in patients with cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul, Republic of Korea.
- Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Gangnam-gu, Seoul, Republic of Korea.
- Department of Radiology, Korea University Ansan Hospital, Korea University College of Medicine, Danwon-gu, Ansan-si, Gyeonggi-do, Republic of Korea.
- Department of Radiology, Korea University Anam Hospital, Korea University College of Medicine, Seongbuk-gu, Seoul, Republic of Korea.
ORCID-Profile: Woo Jin Yang, Myung Gyu Song, Tae-Seok Seo, Sung-Joon Park, Jung Won Kwak
Zitieren
APA
Yang, W. J., Song, M. G., Seo, T. S., Kang, D., Park, S. J., & Kwak, J. W. (2025). Safety of 3-month flushing interval for prevention of occlusion in totally implantable venous access ports: An analysis focused on intraluminal clots. The Journal of Vascular Access. https://doi.org/10.1177/11297298241282822
Vancouver
Yang WJ, Song MG, Seo TS, Kang D, Park SJ, Kwak JW. Safety of 3-month flushing interval for prevention of occlusion in totally implantable venous access ports: An analysis focused on intraluminal clots. The Journal of Vascular Access. 2025. doi:10.1177/11297298241282822
BibTeX
@article{Yang2025,
author = {Yang, Woo Jin and Song, Myung Gyu and Seo, Tae-Seok and Kang, Danbee and Park, Sung-Joon and Kwak, Jung Won},
title = {Safety of 3-month flushing interval for prevention of occlusion in totally implantable venous access ports: An analysis focused on intraluminal clots},
journal = {The Journal of Vascular Access},
year = {2025},
doi = {10.1177/11297298241282822}
}
EUVIMED